Advanced Therapies for Ulcerative Colitis: A Critical Look at Comparative Data

These downloadable slides include expert faculty discussion on the comparable efficacy and risks of specific biologic therapies for treating moderate to severe UC that include TNF inhibitors and non–TNF inhibitor biologics, allowing you to use these comparisons to make optimal treatment decisions for your patients.
Gary Lichtenstein Headshot
Gary R. Lichtenstein, MD
Uma Mahadevan, MD

Downloadable Slideset

Explore the comparable efficacy, risks, and real-world data on specific biologic and small molecules therapies for treating moderate to severe ulcerative colitis.

Gary Lichtenstein Headshot Gary R. Lichtenstein, MD Uma Mahadevan, MD Released: January 24, 2020
Provided by the American Gastroenterological Association
American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org
Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?